Log in

Relevant bibliographies by topics / Tenapanor / Journal articles

To see the other types of publications on this topic, follow the link: Tenapanor.

Journal articles on the topic 'Tenapanor'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Tenapanor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Block, Geoffrey A., David P. Rosenbaum, Andrew Yan, and Glenn M. Chertow. "Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial." Journal of the American Society of Nephrology 30, no. 4 (2019): 641–52. http://dx.doi.org/10.1681/asn.2018080832.

Full text

Abstract:

BackgroundGuidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport.MethodsIn this phase 3 randomized, double-blind trial, we randomly assigned patients with hyperphosphatemia receiving maintenance hemodialysis to receive twice-daily oral tenapanor (3, 10, or 30 mg [the latter down-titrated, if needed]) for 8 weeks. Patients were then rerandomized 1:1 to receive either their previously assigned dose or placebo for a 4-week ‘withdrawal’ pe

APA, Harvard, Vancouver, ISO, and other styles

2

Yuan, Gang, Yili Chen, Li Li, et al. "Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study." International Journal of Clinical Practice 2024 (March 6, 2024): 1–10. http://dx.doi.org/10.1155/2024/1386980.

Full text

Abstract:

Background. Tenapanor is a locally acting selective sodium-hydrogen exchanger 3 inhibitor with the potential to treat sodium/phosphorus and fluid overload in various cardiac-renal diseases, which has been approved for constipation-predominant irritable bowel syndrome in the US. The pharmacokinetics (PK) of tenapanor and its metabolite tenapanor-M1 (AZ13792925), as well as the safety and tolerability of tenapanor, were investigated in healthy Chinese and Caucasian subjects. Methods. This randomized, open-label, single-center, placebo-controlled phase 1 study (https://www.chinadrugtrials.org.cn;

APA, Harvard, Vancouver, ISO, and other styles

3

Suzuki, Naoki, Yuuki Takeda, Akie Kabuto, et al. "Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial." PLOS One 20, no. 6 (2025): e0319319. https://doi.org/10.1371/journal.pone.0319319.

Full text

Abstract:

Introduction Tenapanor is a minimally absorbed, small-molecule inhibitor of sodium/hydrogen exchanger 3 and thus suppresses sodium absorption in the gastrointestinal tract. It is approved by the FDA for the treatment of hyperphosphatemia in dialysis patients. This randomized controlled trial evaluated its efficacy in the treatment of hyperphosphatemia and constipation in hemodialysis patients. Methods Ninety hemodialysis patients were randomized 1:1 to receive either tenapanor or standard care. Randomization was performed using a computer-generated sequence stratified by baseline serum phospho

APA, Harvard, Vancouver, ISO, and other styles

4

Dos Santos, Denise Francisca, Aloisio Pêgo Palacios Luz, Marly Sousa De Araújo, et al. "Tenapanor como terapia para hiperfosfatemia refratária em pacientes submetidos à diálise: revisão sistemática." Brazilian Journal of Health Review 7, no. 1 (2024): 7327–40. http://dx.doi.org/10.34119/bjhrv7n1-599.

Full text

Abstract:

A hiperfosfatemia é uma complicação desafiadora em pacientes em diálise, associada a complicações vasculares e ósseas. O tenapanor, um inibidor do cotransportador de sódio-fósforo no intestino, surge como uma promissora intervenção farmacológica. O presente estudo tem como objetivo avaliar a eficácia do tenapanor como agente terapêutico para hiperfosfatemia refratária em pacientes submetidos à diálise. Este estudo, baseado em uma revisão sistemática da literatura científica, abrange o período de 2014 a 2024, utilizando as bases de dados PubMed (Medline), Cochrane Library e Scientific Electroni

APA, Harvard, Vancouver, ISO, and other styles

5

Tan, Xinjie, Archana Kini, Dorothee Römermann, and Ursula Seidler. "The NHE3 Inhibitor Tenapanor Prevents Intestinal Obstructions in CFTR-Deleted Mice." International Journal of Molecular Sciences 23, no. 17 (2022): 9993. http://dx.doi.org/10.3390/ijms23179993.

Full text

Abstract:

Mutations in the CFTR chloride channel result in intestinal obstructive episodes in cystic fibrosis (CF) patients and in CF animal models. In this study, we explored the possibility of reducing the frequency of obstructive episodes in cftr−/− mice through the oral application of a gut-selective NHE3 inhibitor tenapanor and searched for the underlying mechanisms involved. Sex- and age-matched cftr+/+ and cftr−/− mice were orally gavaged twice daily with 30 mg kg− 1 tenapanor or vehicle for a period of 21 days. Body weight and stool water content was assessed daily and gastrointestinal transit t

APA, Harvard, Vancouver, ISO, and other styles

6

Stamatopoulos, Konstantinos, Nena Mistry, Nikoletta Fotaki, David B. Turner, and Brandon Swift. "Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract—Case Study: Tenapanor." Pharmaceutics 15, no. 12 (2023): 2726. http://dx.doi.org/10.3390/pharmaceutics15122726.

Full text

Abstract:

A physiologically based biopharmaceutics model (PBBM) was developed to predict stool and urine sodium content in response to tenapanor administration in healthy subjects. Tenapanor is a minimally absorbed small molecule that inhibits the sodium/hydrogen isoform 3 exchanger (NHE3). It is used to treat irritable bowel syndrome with constipation (IBS-C). Its mode of action in the gastrointestinal tract reduces the uptake of sodium, resulting in an increase in water secretion in the intestinal lumen and accelerating intestinal transit time. The strategy employed was to perform drug–drug interactio

APA, Harvard, Vancouver, ISO, and other styles

7

Shigematsu, Takashi, Yotaro Une, Kazuaki Ikejiri, Hironori Kanda, Masafumi Fukagawa, and Tadao Akizawa. "Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia." American Journal of Nephrology 52, no. 6 (2021): 496–506. http://dx.doi.org/10.1159/000516156.

Full text

Abstract:

<b><i>Introduction:</i></b> Phosphate binders are used to treat hyperphosphatemia. Some patients have inappropriately controlled serum phosphorus levels, which may occur for many reasons, including a high pill burden and adverse events (AEs). Tenapanor selectively inhibits the passive paracellular transfer of phosphate in the gastrointestinal tract, thereby reducing serum phosphorus levels. This novel mechanism of action may contribute to improved phosphate management. The efficacy and safety of tenapanor have not been evaluated in Japanese patients with high serum phos

APA, Harvard, Vancouver, ISO, and other styles

8

Pergola, Pablo E., David P. Rosenbaum, Yang Yang, and Glenn M. Chertow. "A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)." Journal of the American Society of Nephrology 32, no. 6 (2021): 1465–73. http://dx.doi.org/10.1681/asn.2020101398.

Full text

Abstract:

BackgroundHyperphosphatemia is associated with cardiovascular morbidity and mortality in patients receiving maintenance dialysis. It is unknown whether combining two therapies with different mechanisms of action—tenapanor, an inhibitor of paracellular phosphate absorption, and phosphate binders—is safe and effective for the management of hyperphosphatemia in patients receiving maintenance dialysis.MethodsThis double-blind phase 3 trial enrolled 236 patients undergoing maintenance dialysis with hyperphosphatemia (defined in this trial as serum phosphorus 5.5–10 mg/dl inclusive) despite receivin

APA, Harvard, Vancouver, ISO, and other styles

9

Markham, Anthony. "Tenapanor: First Approval." Drugs 79, no. 17 (2019): 1897–903. http://dx.doi.org/10.1007/s40265-019-01215-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lin, Tiffany, Akram Al-Makki, and Brian Shepler. "Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease." Journal of Pharmacy & Pharmaceutical Sciences 25 (January 16, 2022): 77–83. http://dx.doi.org/10.18433/jpps32284.

Full text

Abstract:

Purpose: This narrative review explores the currently published studies that have evaluated tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) patients on hemodialysis. This medication’s new phosphate lowering mechanism of action reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux by inhibition of the sodium/hydrogen exporter isoform 3 (NHE3). Tenapanor additionally prevents active transcellular phosphate absorption compensation by decreasing the expression of sodium phosphorus 2b transport protein (NaP

APA, Harvard, Vancouver, ISO, and other styles

11

Carney, Ellen F. "Efficacy of tenapanor in hyperphosphataemia." Nature Reviews Nephrology 13, no. 4 (2017): 194. http://dx.doi.org/10.1038/nrneph.2017.27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lobo, Leema, N. Kishore, and Manjari Sharma. "Tenapanor-A Novel Approach for Management of Hyperphosphatemia in End Stage Renal Disease: A Clinical Study Aggregate Review." Journal of Drug Delivery and Therapeutics 14, no. 1 (2024): 176–81. http://dx.doi.org/10.22270/jddt.v14i1.6336.

Full text

Abstract:

The critical importance of phosphate regulation in chronic kidney disease (CKD) has been well understood for decades. But new findings, frequently applicable to routine medical care, continue to evolve. Poor health outcomes, greater morbidity, lowered quality of life, and a higher death rate from cardiovascular disease are all linked to the development of CKD-bone mineral ailment. Increased blood phosphate levels are linked to an increased risk of mortality in hemodialysis patients due to changes in phosphate breakdown and declining renal function as CKD advances.In this setting, according to

APA, Harvard, Vancouver, ISO, and other styles

13

Rosenbaum, David P., Fredric O. Finkelstein, Yang Yang, Rebecca Galvin, and David M. Spiegel. "Impact of Tenapanor in Peritoneal Dialysis." Journal of the American Society of Nephrology 32, no. 10S (2021): 208. http://dx.doi.org/10.1681/asn.20213210s1208a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Brashier, D. B. S., Ajay Kumar, Anuj Singh, and Uday Pratap. "Tenapanor: new approach to counter irritable bowel syndrome with constipation." International Journal of Basic & Clinical Pharmacology 9, no. 7 (2020): 1180. http://dx.doi.org/10.18203/2319-2003.ijbcp20202961.

Full text

Abstract:

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder chronic in nature and characterized predominantly by abdominal pain or discomfort associated with altered bowel habits, diagnosis requires characteristic symptoms during the last 3 months and onset ≥6 months ago. Symptom-based approaches for functional bloating, constipation and diarrhea are best utilised to identify IBS. IBS with constipation exerts significant impairment on work productivity by hampering quality of life. Inadequate relief by existing modalities, persistent hard stools and visceral abdominal pain demande

APA, Harvard, Vancouver, ISO, and other styles

15

Cianciolo, C., S. Barbuto, F. Iacovella, et al. "An update on tenapanor to treat hyperphosphatemia." Drugs of Today 58, no. 1 (2022): 33. http://dx.doi.org/10.1358/dot.2022.58.1.3343689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Siddiqui, S., and B. D. Cash. "Tenapanor for constipation-predominant irritable bowel syndrome." Drugs of Today 56, no. 3 (2020): 203. http://dx.doi.org/10.1358/dot.2020.56.3.3115214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Fadem, Stephen Z., David P. Tietjen, David M. Spiegel, Susan A. Edelstein, Yang Yang, and David P. Rosenbaum. "Patient Education Improves Tenapanor Tolerability in OPTIMIZE Study." Journal of the American Society of Nephrology 34, no. 11S (2023): 129. http://dx.doi.org/10.1681/asn.20233411s1129c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Edelstein, Susan A., Yang Yang, Brett Stephenson, Suling Zhao, Lynae Pagliaro, and Jeanene Fogli. "Patient-Reported Experience with Tenapanor in the OPTIMIZE Trial." Journal of the American Society of Nephrology 32, no. 10S (2021): 537–38. http://dx.doi.org/10.1681/asn.20213210s1537d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yin, Jianyi, Chung-Ming Tse, Boyoung Cha, et al. "A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands." American Journal of Physiology-Gastrointestinal and Liver Physiology 313, no. 2 (2017): G129—G137. http://dx.doi.org/10.1152/ajpgi.00044.2017.

Full text

Abstract:

Na+/H+ exchanger NHE3 mediates the majority of intestinal and renal electroneutral sodium absorption. Dysfunction of NHE3 is associated with a variety of diarrheal diseases. We previously reported that the NHE3 gene ( SLC9A3) has more than 400 single-nucleotide polymorphisms (SNPs) but few nonsynonymous polymorphisms. Among the latter, one polymorphism (rs2247114-G>A), which causes a substitution from arginine to cysteine at amino acid position 799 (p.R799C), is common in Asian populations. To improve our understanding of the population distribution and potential clinical significance of th

APA, Harvard, Vancouver, ISO, and other styles

20

Block, Geoffrey A., David P. Rosenbaum, Maria Leonsson-Zachrisson, et al. "Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis." Journal of the American Society of Nephrology 28, no. 6 (2017): 1933–42. http://dx.doi.org/10.1681/asn.2016080855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sinagra, Emanuele, Francesca Rossi, Dario Raimondo, et al. "Tenapanor for the treatment of irritable bowel syndrome with constipation." Expert Review of Clinical Pharmacology 13, no. 5 (2020): 473–79. http://dx.doi.org/10.1080/17512433.2020.1762570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Soeda, Keisuke, and Hirotaka Komaba. "Navigating How to Initiate Tenapanor Therapy in the Real World." Kidney360 5, no. 7 (2024): 938–40. http://dx.doi.org/10.34067/kid.0000000000000488.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Visconti, Luca, Valeria Cernaro, Sebastiano Calimeri, et al. "The Myth of Water and Salt: From Aquaretics to Tenapanor." Journal of Renal Nutrition 28, no. 2 (2018): 73–82. http://dx.doi.org/10.1053/j.jrn.2017.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Johansson, Susanne, David P. Rosenbaum, Marie Ahlqvist, et al. "Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions." Clinical Pharmacology in Drug Development 6, no. 5 (2017): 466–75. http://dx.doi.org/10.1002/cpdd.346.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Robinson, Jennifer, Chris Dudzenski, and Denise Foy. "Nephrologists Frustrated With FDA Decisions on Roxadustat, Vadadustat, and Tenapanor." Journal of the American Society of Nephrology 33, no. 11S (2022): 929. http://dx.doi.org/10.1681/asn.20223311s1929c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Shima, Hisato, Hiroyoshi Nakatsuji, Manabu Sakaki, Yoshihide Murakami, and Takumi Hamao. "Tenapanor‒induced drug eruption in hemodialysis patient： A case report." Nihon Toseki Igakkai Zasshi 58, no. 4 (2025): 215–18. https://doi.org/10.4009/jsdt.58.215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sijabat, Landong, and Guinanti Novettiandari. "PHARMACOLOGIC TREATMENT OF THE IRRITABLE BOWEL SYNDROME: A COMPREHENSIVE SYSTEMATIC REVIEW." Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425) 10, no. 5 (2024): 26–34. http://dx.doi.org/10.61841/ypxr6c52.

Full text

Abstract:

Background: Abdominal pain and changes in stool frequency are two of the symptoms of Irritable Bowel Syndrome (IBS), a chronic gastrointestinal illness. As there is no known cure, treatment focuses on symptom management. Patients struggle with psychological and emotional issues that lower their quality of life. Clinical trials have demonstrated the therapeutic effects of several therapeutic drugs, which may improve GI symptoms and general quality of life. Effective treatment of IBS requires an understanding of the connection between pharmaceutical medicines and the illness. Methods: Following

APA, Harvard, Vancouver, ISO, and other styles

28

Block, Geoffrey A., David P. Rosenbaum, Maria Leonsson-Zachrisson, et al. "Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis." Clinical Journal of the American Society of Nephrology 11, no. 9 (2016): 1597–605. http://dx.doi.org/10.2215/cjn.09050815.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Akizawa, Tadao, Yu Sato, Kazuaki Ikejiri, Hironori Kanda, and Masafumi Fukagawa. "Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients." Kidney International Reports 6, no. 9 (2021): 2371–80. http://dx.doi.org/10.1016/j.ekir.2021.06.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zielińska, Marta, Andrzej Wasilewski, and Jakub Fichna. "Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome." Expert Opinion on Investigational Drugs 24, no. 8 (2015): 1093–99. http://dx.doi.org/10.1517/13543784.2015.1054480.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Okada, Kazuyoshi, Manabu Tashiro, Ikuko Shimizu, Tomoko Inoue, and Jun Minakuchi. "Impact of switching from lanthanum carbonate to tenapanor on CKD‒MBD management." Nihon Toseki Igakkai Zasshi 58, no. 1 (2025): 31–33. https://doi.org/10.4009/jsdt.58.31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Moro, L. "Tenapanor. Na+/H+ exchanger 3 (NHE3) inhibitor, Treatment of gastrointestinal and cardiorenal diseases." Drugs of the Future 43, no. 6 (2018): 395. http://dx.doi.org/10.1358/dof.2018.043.06.2802349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Li, Qian, Andrew J. King, Liansheng Liu, Yaohui Zhu, Jeremy S. Caldwell, and Pankaj J. Pasricha. "Tenapanor Reduces IBS Pain Through Inhibition of TRPV1-Dependent Neuronal Hyperexcitability In vivo." American Journal of Gastroenterology 112 (October 2017): S255. http://dx.doi.org/10.14309/00000434-201710001-00484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Johansson, Susanne A., Mikael Knutsson, Maria Leonsson-Zachrisson, and David P. Rosenbaum. "Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study." Clinical Pharmacology in Drug Development 6, no. 5 (2017): 457–65. http://dx.doi.org/10.1002/cpdd.341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Lacy, Brian, Yang Yang, and David Rosenbaum. "S171 Tenapanor Treatment Success for IBS-C Symptoms Increases with Duration of Therapy." American Journal of Gastroenterology 118, no. 10S (2023): S129. http://dx.doi.org/10.14309/01.ajg.0000950324.37170.3f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Stephenson, B., G. Chertow, Y. Yang, and D. Rosenbaum. "PUK2 Hospitalization in Patients Receiving Maintenance Dialysis with Hyperphosphatemia Randomized to Tenapanor or Sevelamer." Value in Health 24 (June 2021): S234. http://dx.doi.org/10.1016/j.jval.2021.04.1170.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Johansson, Susanne, David P. Rosenbaum, Johan Palm, et al. "Tenapanor administration and the activity of the H+-coupled transporter PepT1 in healthy volunteers." British Journal of Clinical Pharmacology 83, no. 9 (2017): 2008–14. http://dx.doi.org/10.1111/bcp.13313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Rosenbaum, David P., Andrew Yan, and Jeffrey W. Jacobs. "Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers." Clinical Drug Investigation 38, no. 4 (2018): 341–51. http://dx.doi.org/10.1007/s40261-017-0614-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Pace, Rory C., David P. Tietjen, David M. Spiegel, et al. "The Positive Impact of Patient Education on Tenapanor Adherence 295 in the OPTIMIZE Study." Nephrology Nursing Journal 52, no. 3 (2025): 295. https://doi.org/10.37526/1526-744x.2025.52.3.295.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

B., Akhila N. Navya Sree K. Mounika M. Sreya E. Anusha B. Manasa. "A Review on FDA Approved Drugs for Chronic Kidney Disease." International Journal of Pharmaceutical Sciences 2, no. 12 (2024): 966–76. https://doi.org/10.5281/zenodo.14339742.

Full text

Abstract:

Chronic kidney disease is a progressive disease with no cure and high morbidity and mortality occurs in general adult population, especially in people with diabetes and Hypertension. CKD is characterized by the presence of kidney damage  or an estimated glomerular filtration rate of less than 60/ml/min persisting for 3months or more .Kidney function can be improved by pharmacological and Non pharmacological therapies, FDA has approved the drugs namely Empagliflozin, Nedosiran, Tenapanor, Budesonide, Vadadustat which act by improving therapeutic action. recently some advanced treatments ar

APA, Harvard, Vancouver, ISO, and other styles

41

Johansson, Susanne, Maria Leonsson-Zachrisson, Mikael Knutsson, et al. "Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders." Clinical Pharmacology in Drug Development 6, no. 5 (2016): 448–56. http://dx.doi.org/10.1002/cpdd.307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Silva, Arnold L., German T. Hernandez, David M. Spiegel, et al. "Safety Analysis of Tenapanor Monotherapy vs. Sevelamer Carbonate in Patients on Maintenance Dialysis with Hyperphosphatemia." Journal of the American Society of Nephrology 34, no. 11S (2023): 129. http://dx.doi.org/10.1681/asn.20233411s1129b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Cernaro, Valeria, Elisa Longhitano, Chiara Casuscelli, Luigi Peritore, and Domenico Santoro. "Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor." International Journal of Nephrology and Renovascular Disease Volume 17 (May 2024): 151–61. http://dx.doi.org/10.2147/ijnrd.s385826.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Block, Geoffrey A., David P. Rosenbaum, Andrew Yan, Peter J. Greasley, Glenn M. Chertow, and Myles Wolf. "The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia." Nephrology Dialysis Transplantation 34, no. 2 (2018): 339–46. http://dx.doi.org/10.1093/ndt/gfy061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

King, Andrew J., Matthew Siegel, Ying He, et al. "Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability." Science Translational Medicine 10, no. 456 (2018): eaam6474. http://dx.doi.org/10.1126/scitranslmed.aam6474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Herekar, Anam, Dhanush Shimoga, Asad Jehangir, et al. "Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management." Clinical and Experimental Gastroenterology Volume 16 (June 2023): 79–85. http://dx.doi.org/10.2147/ceg.s384251.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lembo, Anthony, Susan Edelstein, Yang Yang, and David P. Rosenbaum. "Mo1396: LONG TERM TREATMENT WITH TENAPANOR IMPROVES ABDOMINAL PAIN AND OTHER ABDOMINAL SYMPTOMS ASSOCIATED WITH IBS-C." Gastroenterology 162, no. 7 (2022): S—757. http://dx.doi.org/10.1016/s0016-5085(22)61788-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Inaba, Masaaki, Yotaro Une, Kazuaki Ikejiri, Hironori Kanda, Masafumi Fukagawa, and Tadao Akizawa. "Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial." Kidney International Reports 7, no. 2 (2022): 177–88. http://dx.doi.org/10.1016/j.ekir.2021.11.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Johansson, Susanne, David P. Rosenbaum, Mikael Knutsson, and Maria Leonsson-Zachrisson. "A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers." Clinical and Experimental Nephrology 21, no. 3 (2016): 407–16. http://dx.doi.org/10.1007/s10157-016-1302-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Sprague, Stuart M., Jill M. Meyer, David P. Rosenbaum, Yang Yang, Suling Zhao, and David M. Spiegel. "Optimal Initiation of Tenapanor Treatment Analyzed by Baseline Phosphate Binder Dose: A Subanalysis of the OPTIMIZE Study." Journal of the American Society of Nephrology 34, no. 11S (2023): 128. http://dx.doi.org/10.1681/asn.20233411s1128c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!